Successful treatment of recalcitrant pityriasis lichenoides et varioliformis acuta with baricitinib: A case report
Nouf AlMuhanna, AlAnoud A AlSalman, Mishari Tariq Alrubaiaan, Mohammed Abdulaziz AlOsaimi, Nouf Abdulaziz Almagushi, Ahmed Alhumidi · 2026
Read Successful treatment of recalcitrant pityriasis lichenoides et varioliformis acuta with baricitinib: A case report by Nouf AlMuhanna, AlAnoud A AlSalman, Mishari Tariq Alrubaiaan, Mohammed Abdulaziz AlOsaimi, Nouf Abdulaziz Almagushi, Ahmed Alhumidi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13319706.txt.
Description
Nouf AlMuhanna and co-authors report, in 2026, successful use of baricitinib for a stubborn inflammatory skin disease in a twelve-year-old boy. The condition, abbreviated PLEVA, causes recurrent crops of red spots that can blister, die and crust, leaving pitted scars. Evidence points to misdirected T-cell activity, and standard treatments from antibiotics to immune suppressants often help only partly or briefly.
The boy had a generalised itchy eruption for two years, with a history of repeated tonsillitis and many antibiotic courses. Baricitinib blocks Janus kinase signalling, a pathway implicated in several T-cell skin diseases, and is approved for eczema and hair loss. His disease improved on the drug, the authors report, suggesting Janus kinase inhibition deserves study as an option for treatment-resistant cases.
Catalog record
| CREATOR | Nouf AlMuhanna, AlAnoud A AlSalman, Mishari Tariq Alrubaiaan, Mohammed Abdulaziz AlOsaimi, Nouf Abdulaziz Almagushi, Ahmed Alhumidi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 8 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |